Vivantes Netzwerk fuer Gesundheit GmbH
- Address
- Dieffenbachstrasse 1, Kreuzberg, 10967 Berlin, Germany
Vivantes Netzwerk fuer Gesundheit GmbH - Advanced Cancer and Blood Disorders Research Center
Vivantes Netzwerk fuer Gesundheit GmbH is a prominent clinical research institution in Germany specializing in oncology and hematology trials. The center demonstrates particular expertise in B-cell lymphomas and acute myeloid leukemia, conducting multiple phase III trials evaluating novel immunotherapies, bispecific antibodies, and targeted combination treatments. Their research portfolio encompasses both solid tumors and hematologic malignancies, with a strong focus on breakthrough therapies and personalized medicine approaches.
- Hematologic malignancies including multiple myeloma, acute myeloid leukemia, acute lymphoblastic leukemia, and various B-cell lymphomas (follicular, diffuse large B-cell, mantle cell, Hodgkin lymphoma)
- Advanced solid tumors with emphasis on non-small cell lung cancer, breast cancer (HR+/HER2-), metastatic colorectal cancer, bladder cancer, and prostate cancer
- Novel therapeutic modalities including gene therapy for hemophilia B, bispecific antibodies, antibody-drug conjugates, CAR-T cell approaches, and immune checkpoint inhibitors
- Neurological conditions including status epilepticus, epilepsy with focal-onset and generalized tonic-clonic seizures
The center actively participates in international collaborative research networks, particularly through German multicenter study groups such as GMMG (German-Speaking Myeloma Multicenter Group) and GMALL (German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia). Vivantes demonstrates strong capabilities in evaluating combination immunotherapy regimens, conducting maintenance therapy trials, and assessing minimal residual disease outcomes. Their cardiovascular and nephrology research includes trials for heart failure, chronic kidney disease with hypertension, and acute myocardial infarction, alongside respiratory disease studies in idiopathic pulmonary fibrosis. The institution's diverse trial portfolio reflects its commitment to advancing treatment options across multiple therapeutic areas while maintaining rigorous safety and efficacy standards.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 6 therapeutic areas and 15 of 65 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 63 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1AstraZeneca AB1active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vivantes Netzwerk fuer Gesundheit GmbH
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2) | Apcintex Limited | Phase II | Not Recruiting | Nov 2023 | Jan 2025 |
IMP list
lock Showing 1 of 65 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 4 | Unknown | 2023-02-24 | 2025-12-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.